Biotech Values

[genisi]

GHDX/Oncotype DX data in DCIS

When rigorous* pathologic assessment is being used to define 'low risk' vs 'high risk' DCIS patients, docs can evaluate the risk of recurrence and decide on treatment accordingly. Since most patients get a surgery anyway (hence parameters like tumor size and surgical margins status are available), and chemotherapy is generally not required, the question is about adjuvant radiation. GHDX will need to convince docs that OncotypeDX score is a better prognosticator than these pathologic criteria.

* As in study E5194 ( http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773217/?tool=pubmed ) mentioned in the PR you've posted.